BioNTech Se
Q2 2023 Earnings Call
Aug 07, 2023, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Welcome to BioNTech s second-quarter 2023 update call. I would like to hand the call over to Dr. Victoria Meissner, vice president of strategy and investor relations. Please go ahead.
Victoria Meissner -- Vice President, Strategy and Investor Relations
Thank you. Good morning and afternoon. Thank you for joining us today for BioNTech's second-quarter 2023 earnings call. As a brief reminder, the slides that accompany this call and the second-quarter 2023 press release that was issued this morning can be found in an investor section of our website.
As outlined on Slide 2, you can see all our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings made with the U.S. Securities and Exchange Commission. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of these statements. On Slide 3, you can find the agenda for today's call.
Today, I'm joined by the following members of BioNTech's management team: our CEO and co-founder; Uğur Şahin; Ozlem Tureci, our chief medical officer and co-founder; Jens Holstein, our chief financial officer; and Ryan Richardson, our chief strategy officer. I would like to turn the call over to Uğur Şahin.
Uğur Şahin -- Co-Founder and Chief Executive Officer
Thank you, Victoria. A warm welcome to all the call participants. We appreciate your continued support. Today.
I will summarize our second-quarter 2023 highlights and priorities before I pass the call over to my team to provide some further details. Slide 5. Let me start reiterating our 2023 strategic priorities that we set at the beginning of the year and highlight our recent progress executing against them. We pursue our priority to expand and sustain our COVID-19 leadership further by advancing our next-generation and combination vaccine candidates and by advancing key Comirnaty features. During this quarter, we receive recommendations from regulatory authorities and the World Health Organization on the composition of the adapted COVID-19 vaccine for the 2023-2024 season. Based on these recommendations, we, together with our partner, Pfizer, have submitted regulatory packages from omicron XBB.1.5-adapted monovalent COVID-19 vaccine to the U.S.